



Peptidomic changes in human serous colorectal cancer patients

Jianghao Xu^{1#}, Xingling Li^{2#}, Wenlong Chen^{3#}, Steven Yan Cheng², Jie Cheng⁴, Cong Chen⁵

¹Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ²Department of Medical Genetics, Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China; ³Department of Colorectal Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ⁴Center for Reproductive Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; ⁵Department of Neurology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Contributions: (I) Conception and design: C Chen; (II) Administrative support: S Cheng, J Cheng, C Chen; (III) Provision of study materials or patients: J Cheng, C Chen; (IV) Collection and assembly of data: J Xu, W Chen, X Li; (V) Data analysis and interpretation: J Xu, W Chen, X Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Cong Chen, MD. Department of Neurology, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China. Email: chencong2006nyd@163.com; Jie Cheng, MD. Center for Reproductive Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 845 Lingshan Road, Shanghai 200135, China. Email: chengjiehmzx@126.com; Steven Yan Cheng, PhD. Department of Medical Genetics, Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing 211166, China. Email: sycheng@njmu.edu.cn.

Background: Colorectal cancer (CRC) is the third most common cancer worldwide and one of the leading causes of cancer-related death. Peptidomics, considered a novel branch of proteomics, has an increasing range of applications in the screening, diagnosis, prognosis, and even monitoring of cancer. However, there is little information for peptidomics analysis in CRC.

Methods: In this study, a comparative peptidomic profiling was analyzed in 3 CRC tissue samples and 3 adjacent intestinal epithelial tissue samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Results: Among the total 133 nonredundant peptides identified, 59 were significantly differentially expressed in the CRC samples and benign colonic epithelium conditions [fold change (FC) >2, P<0.05]. Totals of 25 up-regulated and 34 down-regulated peptides were detected, respectively. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were applied to predict the possible functions of these relevant precursor proteins. To clearly identify the potential interaction network of peptide precursors, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) was used to determine protein interactions and a possible central role in CRC.

Conclusions: Our results for the first time revealed the differentially expressed peptides between the serous CRC tissue and the adjacent intestinal epithelial tissue samples, and these prominently variable peptides might have an important potential role in occurrence and development of CRC.

Keywords: Profiling analysis; colorectal cancer (CRC); peptidomic

Submitted Nov 21, 2022. Accepted for publication Apr 14, 2023. Published online Apr 29, 2023.

doi: 10.21037/jgo-23-188

View this article at: <https://dx.doi.org/10.21037/jgo-23-188>

Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide and the third leading cause of cancer-related deaths, with 160,000 cases diagnosed annually in the USA (1). Surgery, radiotherapy, and chemotherapy are applied as the most common treatments for CRC (2). However, each

treatment has its own indications, benefits, side effects, and potential risks. Besides, the recurrence and mortality rate after primary therapy of CRC patients is high (3). The prognosis of CRC patients may be confounded by differences in stage at presentation, tumor site, preexisting comorbidities, and type of treatment received (4). Thus, it

is urgent and necessary to develop innovative therapeutic strategies for the treatment of this lethal disease. In recent years, targeted therapies, developed as promising alternative therapeutic options, have created many novel approaches for detection and treatment monitoring of CRC, such as tumor-derived exosomes (5), circulating tumor cells (6), soluble molecules (7) and miRNAs (8). For example, FOLFOX-resistance in advanced CRC is significantly associated with upregulation and downregulation of several serum miRNAs like miR-19a. However, there are still no reliable biomarkers for the diagnosis of CRC.

Peptidomics is an emerging branch of proteomics that targets endogenously produced protein fragments (9), called endogenous peptides (up to ~20 kDa), which could dynamically monitor the status of a tissue or sample. It has also been applied to screen for activators, inhibitors, proteases, and protein substrates (10). Peptides are important bioactive molecules in many physiological processes, including cancer (10,11). However, peptidomic analysis of CRC was unclear. Thus, we carried out a quantitative liquid chromatography/mass spectrometry (LC-MS) study on human serous CRC tissue and adjacent intestinal epithelial tissue to explore the relevant genes and precursor proteins. Furthermore, these different peptides between intestinal epithelial tissue and serous CRC tissue were determined and analyzed by bioinformatics. Our study aimed to identify potential antitumor peptides connected with CRC and lay a foundation for further research on possible therapeutic targets. We present the following article in accordance with the STREGA reporting

checklist (available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-188/rc>).

Methods

Sample collection

We collected 3 groups of the serous CRC tissue and paracarcinoma tissue samples from the First Affiliated Hospital of Nanjing Medical University. The patients with CRC met the following inclusion criteria: (I) older than 18 years, (II) capable of giving informed consent, and (III) with serous CRC confirmed by pathology. Patients were excluded if they had any of the following: (I) other cancers; (II) a history of other cancers; (III) previous radiotherapy or chemotherapy before surgery; (IV) other diseases related to the cardiovascular system, respiratory system, genitourinary system, digestive system; or (V) acute infection. Clinical characteristics of all the patients involved are shown in *Table 1*. All samples were confirmed by pathology. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (No. 2018-SRFA-268). The patients were informed about the research and signed medical informed consent documents. All the tissues were collected immediately after surgery and were stored at -80 °C until use.

Peptides extraction and purification

An appropriate amount of each sample was taken for extraction of this experiment. Briefly, after grinding in liquid nitrogen, samples were mixed by blowing in protein lysate. Phenylmethylsulfonyl fluoride (PMSF), 2 mM ethylenediamine tetraacetic acid (EDTA), 10 mM dithiothreitol (DTT), were added in the final solution of 1 mM concentration, which was then homogenized on ice with ultrasound and incubated on ice for 5 minutes. The mixture was centrifuged at 12,000 r/min at 4 °C for 30 minutes and the supernatant was collected into a new centrifugal tube. After being concentrated by Bradford method, an equivalent amount of protein was taken for reduction alkylation treatment. Prior to concentration measurement, equal amounts were subjected to centrifugal ultrafiltration in a 10 kd protein ultrafiltration tube (4 °C 12,000 r/min 30 min), the penetrating fluid was collected, and applied to the peptide. The polypeptide samples were desalted by C18 column, and the peptides were desalted by

Highlight box

Key findings

- Our results revealed differentially expressed peptides between the serous colorectal cancer tissue and the adjacent intestinal epithelial tissue samples.

What is known and what is new?

- There is little information for peptidomics analysis in CRC.
- We reported that 59 were significantly differentially expressed in the CRC samples and benign colonic epithelium conditions (fold changes >2, P<0.05). 25 up-regulated and 34 down-regulated peptides were detected respectively.

What is the implication, and what should change now?

- These prominently variable peptides might have an important potential role with the specific function and mechanism of them in the occurrence and development of CRC.

Table 1 The basic clinical information of colorectal patients

No.	Age, years	Gender	Stage
1	63	Male	T3N2bM0
2	63	Male	T3N1bM0
3	52	Male	T3N2AM0

vacuum freeze drying.

ITRAQ labeling

The peptides were dissolved with 0.5 M triethylammonium bicarbonate (TEAB) and labeled according to the instructions of the iTRAQ-8 standard kit (SCIEX, Toronto, Canada). The samples were labeled and mixed. The mixed peptide was then graded and separated using the Ultimate 3000 HPLC system (Thermo Fisher, Waltham, MA, USA). The column was Durashell-C18 (5 m, 100 Å, 4.6×250 mm). Acetonitrile (ACN) concentration was gradually increased under alkaline conditions. The separation of peptides was carried out at a flow rate of 1 mL/min, and 1 tube was collected every minute. A total of 42 secondary fractions were collected and combined into 12 groups. The Strata-X column was desalted and vacuum dried. The serous CRC tissue samples were labeled with reagents 116, 118, and 120, and the normal intestinal epithelial tissue samples were labeled with reagents 115, 117, and 119. The labeled peptides were frozen at -80 °C until identified analysis by liquid chromatography (LC)-tandem mass spectrometry (MS/MS).

LC-MS/MS combination analysis

The MS data was collected using the TripleTOF 5600 + liquid mass combined system (SCIEX). The polypeptide sample was dissolved in 2% CANACN with 0.1% formic acid. A TripleTOF 5600 plus mass spectrometer coupled to the Eksigent nanoLC system (SCIEX) was used for the analysis of formic acid. The polypeptide solution was added to the C18 capture column (5 m, 100 m, 20 mm) at a time gradient of 90 minutes and a flow rate of 300 µL/min. At C18 Gradient elution was performed on the analysis column (3 m, 75 m, 150 mm). The 2 mobile phases were buffer A (2% ACN/0.1% formic acid/98% H₂O) and buffer B (98% ACN/0.1% formic acid/2% H₂O). For information dependent collection (IDA), the ion accumulation time was 250 ms. The first order mass spectra was scanned and the

second order mass spectra of 30 precursor ions was collected at the ion accumulation time of 50 ms in 350–1,500 m/z. The spectrum of MS1 was collected in the range of 100 to 1,500 m/z, and the spectrum of MS2 was collected in the range of 100 to 1,500 m/z. The dynamic exclusion time was 15 seconds.

Protein identification

This experiment adopted the basic procedure of proteome identification based on MS AB Sciex 5600 and the software ProteinPilot™ V4.5 was used. ProteinPilot was used to search with all possible modification types in mind. The fault-tolerant matching function can retrieve more results than similar software under the premise of guaranteeing the reliability of identification results. For ProteinPilot in line with the results of identification, we further filtered the data and concluded that for unused score ≥1.3, the credibility level was above 95%, each protein containing at least 1 unique peptide is a credible protein, and those that did not meet the above requirements were not included in this report.

Bioinformatics analysis

The MW/PI online tool (http://web.expasy.org/compute_pi/) was applied to calculate the isoelectric point (pI) of each peptide. For further research, UniProt Database release 2015_5 (<http://www.uniprot.org/>), including cellular component, biological process, and molecular function, was used to perform a Gene Ontology (GO) analysis to investigate the potential functions of the peptide protein precursors. We also used Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to reveal the networks of these peptide precursors. Genes and proteins associated with differential peptides were analyzed in various respects by widely practical database including the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; <http://string-db.org/cgi/input.pl>), The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov>), OncoLnc (<http://www.oncolnc.org/>) for protein interaction, mutated genes determination, and survival forecast, respectively. Eventually, the functional data for significantly differentiated peptides were discussed.

Statistical analysis

The 2-tailed Student's *t*-test was applied for statistical analysis and *P* < 0.05 was considered significant. Peptides




Figure 1 Differentially expressed peptides between the CRC tissue and adjacent epithelial tissue. (A) Of 133 non-redundant peptides, 59 peptides derived from 38 precursor proteins were significantly differentially expressed ($FC > 2$, $P < 0.05$), including 25 up-regulated peptides and 34 down-regulated peptides. (B) Heat map of the differentially expressed peptides between the CRC tissues and the adjacent intestinal epithelial tissues with $FC \geq 2$ and $P < 0.05$ (the red lines indicate the peptides upregulated in the serous colorecta cancer tissues, and the green lines indicate the peptides downregulated peptides in the serous colorectal cancer tissues). (C) Volcano plot analysis of the peptides identified from the colorectal cancer tissues and the adjacent intestinal epithelial tissues ($FC \geq 2$ and $P < 0.05$). The mean \pm SD in the graph presents the relative levels from 3 replications. N indicates tumor adjacent epithelial tissue; T indicates tumor tissue. FC, fold change; CRC, colorectal cancer; SD, standard deviation.

with fold change (FC) > 2 and $P < 0.05$ were deemed to be a significant variation.

Results

Peptide profiling of serous CRC tissue and adjacent epithelial tissue from patients

Intracellular Peptides from the CRC and the adjacent epithelial tissue (control groups) were directly analyzed by LC-MS/MS after tandem mass tag (TMT) labeling. A total of 133 non-redundant peptides were identified by comparing 2 groups (CRC group and control group)

(Table S1). Among them, 59 peptides derived from 38 precursor proteins had significantly different expression ($FC > 2$, $P < 0.05$), including 25 up-regulated peptides and 34 down-regulated peptides between CRC and adjacent epithelial tissues (Figure 1A). Volcano plot and heat maps were used to visualize the peptides with the highest FC (Figure 1B,1C). All of the differentially expressed peptides are listed in Table 2.

Characterization and cleavage site analysis of the 59 differentially expressed peptides

The general characteristics of the peptides were analyzed

Table 2 Detailed information of genes and precursor proteins associated with differential peptides in this study

Gene name	Protein_ID	Full name	Peptide	Fold change	P value	Potential function ^a
Up-regulated peptides						
IFITM3	Q01628	Interferon-induced transmembrane protein 3	APHNPAPPTSTV	14.94	0.01094	Antiviral defense, immunity, innate immunity
HIST1H2BC	P62807	Histone H2B type 1-C/E/F/G/I	TSREIQTAV	13.24	0.01894	Chromosome, nucleosome core, nucleus
HIST2H3A	Q71DI3	Histone H3.2	DLRFQSSAV	11.88	0.00015	DNA-binding
HBB	P68871	Hemoglobin subunit beta	VNVDEVGGGEALGR	9.91	0.00000	Hypotensive agent, vasoactive
KRT18	P05783	Keratin, type I cytoskeletal 18	SVQAPSYGARPV	9.15	0.00006	Disease mutation
DEFA3	P59666	Neutrophil defensin 3	DCYCRIPA	8.18	0.00125	Antibiotic, antimicrobial, defensin, fungicide
PRDX5	P30044	Peroxisome oxidoreductin-5, mitochondrial	SLAPNIISQL	7.37	0.00357	Antioxidant, oxidoreductase, peroxidase
HIST2H2AA3	Q6FI13	Histone H2A type 2-A	AQGGVLPNIQAV	6.94	0.0000005	DNA-binding
RPS11	P62280	40S ribosomal protein S11	ADIQTERAYQKQPT	6.87	0.00016	Ribonucleoprotein, ribosomal protein, RNA-binding, rRNA-binding
HBA1	P69905	Hemoglobin subunit alpha	VLSPADKTNV	6.45	0.00018	Oxygen transport, transport
ALB	P02768	Serum albumin	AASQAALGL	6.43	0.01615	Copper, lipid-binding, metal-binding, zinc
HIST1H1E	P10412	Histone H1.4	AAAGYDVEK	5.55	0.01149	DNA-binding
GSTP1	P09211	Glutathione S-transferase P	NLPINGNGKQ	4.81	0.00008	Transferase
RPS27L	Q71UM5	40S ribosomal protein S27-like	TTVFSHAQTV	3.28	0.01002	Ribonucleoprotein, ribosomal protein
H3F3A	P84243	Histone H3.3	GALQEASEAYLV	3.03	0.00154	DNA-binding
LTF	P02788	Lactotransferrin	QAIAENRADAV	2.99	0.02286	Antibiotic, antimicrobial, DNA-binding, heparin-binding, Hydrolase, protease, serine protease
RPL37A	P61513	60S ribosomal protein L37a	AGGAWTYNTT	2.98	0.02583	Ribonucleoprotein, ribosomal protein
SNRPE	P62304	Small nuclear ribonucleoprotein E	TLLQSVSN	2.23	0.00000	Ribonucleoprotein, RNA-binding
Down-regulated peptides						
–	P0DOX7	Immunoglobulin kappa light chain	DSTYLSSTLTLSK	0.60	0.01802	Disulfide bond
IGKV2-30	P06310	Immunoglobulin kappa variable 2-30	DVVMTSQSPSLPV	0.60	0.01501	Adaptive immunity, immunity
A2M	P01023	Alpha-2-macroglobulin	AIGYLNTGYQR	0.51	0.01666	Protease inhibitor, serine protease inhibitor
HIST1H4A	P62805	Histone H4	LENVIRDAVT	0.51	0.02907	DNA-binding

Table 2 (continued)

Table 2 (continued)

Gene name	Protein_ID	Full name	Peptide	Fold change	P value	Potential function ^a
ANXA2P2	A6NMY6	Putative annexin A2-like protein	LLYLGGDD	0.49	0.00055	Calcium, calcium/phospholipid-binding
FGA	P02671	Fibrinogen alpha chain	GEGDFLAEGGGVR	0.44	0.02229	Adaptive immunity, blood coagulation, hemostasis, immunity, innate immunity
HNRNPA2B1	P22626	Heterogeneous nuclear ribonucleoproteins A2/B1	GGPYGGGNYGP	0.39	0.00604	Ribonucleoprotein, RNA-binding
VIP	P01282	VIP peptides	NISEDPVPV	0.39	0.00489	Hormone
VIME	P08670	Vimentin	ASSPGGVYATRSSAV	0.37	0.00630	Host-virus interaction
CFL1	P23528	Cofilin-1	ASGVAVSDGVIVK	0.36	0.00724	Actin-binding
CNN1	P51911	Calponin-1	FEPGLGMEH	0.34	0.00270	Phosphoprotein
PTBP1	P26599	Polypyrimidine tract-binding protein 1	MDGIVPDIAVGTK	0.33	0.00167	Activator, repressor, RNA-binding
HNRNPR	O43390	Heterogeneous nuclear ribonucleoprotein R	QDTYGQQWK	0.33	0.00550	Ribonucleoprotein, RNA-binding
RPL31	P62899	60S ribosomal protein L31	KNLQTVNVNEN	0.33	0.00612	Acetylation, phosphoprotein
TMSB10	P63313	Thymosin beta-10	ADKPDMGEIAS	0.32	0.00151	Actin-binding
AHNAK	Q09666	Neuroblast differentiation-associated protein AHNAK	ADVDISGPK	0.21	0.00025	Acetylation, isopeptide bond, methylation, phosphoprotein, Ubl conjugation
RTN4	Q9NQC3	Reticulon-4	AAPVPTAPAAGAPL	0.21	0.00013	Neurogenesis
TMSB4X	P62328	Thymosin beta-4	SDKPDMAEIEK	0.14	0.00002	Actin-binding
PYY	P10082	Peptide YY	DGPDTLISK	0.07	0.00062	Secreted
KRT8	P05787	Keratin, type II cytoskeletal 8	VSESSDVLPK	0.07	0.00033	Host-virus interaction

^a, data is from Uniprot; <https://www.uniprot.org/>.

including amino acid numbers, molecular weights (MW), and pI. The MW and pI of the 59 differentially expressed peptides are shown in *Figure 2A* and *2B*. Significantly, MWs' range were mainly distributed between 1,200 and 2,200 Da. Meanwhile, the largest proportion of peptide pI was ranged from 3 to 10 of all peptides. The distribution of the MW relative to the pI was also investigated because of the contribution of amino acid composition and MW distribution to the specific pI distribution (*Figure 2C*). Given that peptidomics profiling is informative to determine protein degradation activity in various types of cancer, the cleavage sites of the differentially expressed peptides at the N- and C-terminals (C-terminal amino acid of the

preceding peptide, N-terminal amino acid of the identified peptide, C-terminal amino acid of the identified peptide, and N-terminal amino acid of the subsequent peptide) were analyzed for investigation differences in 2 groups (*Figure 2D, 2E*). In the up-regulated group, the top 4 frequency of cleavage sites contained the amino acids were valine (V), histidine (H), threonine (T), and alanine (A). In the down-regulated group, the top 4 variation cleavage sites contained the amino acids lysine (K), alanine (A), arginine (R), and serine (S). Based on the previous studies, multiple peptides may derive from the same precursor protein. *Figure 2F* lists the precursor proteins and demonstrates that H2A2A had the highest number of related peptides.




Figure 2 Features of the differentially expressed peptides. (A) MWs of the peptides. (B) pI of the peptides. (C) Scatter plot of the MWs versus the pI. (D) The N- and C-terminal amino acid distribution of the identified and preceding peptides in the up-regulated group. (E) The N- and C-terminal amino acid distribution of the identified and preceding peptides in the down-regulated group. (F) Precursor proteins produce different numbers of peptides. The mean \pm SD in the graph presents the relative levels from three replications. MW, molecular weight; pI, isoelectric point; SD, standard deviation.

GO and pathway analysis of the precursor proteins of the differentially expressed peptides

Considering the function of precursor inactivator of many peptides, we performed GO and pathway analyses to determine potential roles for these peptides based on their precursor proteins in CRC. Antibacterial humoral response, antimicrobial humoral response, negative regulation of macromolecule metabolic process, biological regulation, regulation of cellular process, and so on, were identified as the most highly enriched biological processes related to the differentially expressed peptides identified (Figure 3A). For cellular components, antioxidant activity, protein binding, oxygen binding, oxidoreductase activity, acting on peroxide as acceptor, iron ion binding, and so on, were accumulated (Figure 3B). Regarding molecular functions, nucleus, catalytic step 2 spliceosome, intermediate filament cytoskeleton, contractile fiber part, vacuolar part, cytosolic small ribosomal subunit, and so on, were the most highly abundant (Figure 3C). Besides, the KEGG pathway analysis revealed that the identified peptides were involved in malaria, drug metabolism-cytochrome P450, tyrosine

metabolism, metabolism of xenobiotics by cytochrome P450, aminoacyl-tRNA biosynthesis, prostate cancer, and others (Figure 3D).

Potential function analysis of precursor proteins

Given the various differential peptides detected, 38 precursor proteins were determined eventually and there are 18 up-regulated and 20 down-regulated targets classified in Table 2. Obviously, FCs in up-regulated proteins (2.3–14.94 orders) were more drastic than in down-regulated proteins (0.07–0.6), revealing the primary variation in elevating proteins expressions. To evaluate the possible role of proteins, potential functions of 10 top variable proteins were investigated in the Web of Science database, and included 5 up-regulated proteins: IFITM3, HIST1H2BC, HIST2H3A, HBB, and KRT18 and 5 down-regulated proteins: IGKV2-30, A2M, HIST1H4A, ANXA2P2, and FGA (12–18) (Table 3). The possible roles of proteins had been identified in some previous studies, such as prognostic relevance, biomarkers, and the Notch1 pathway. Notably, some variable precursors had an unclear role in our




Figure 3 GO and KEGG pathway analysis of the precursor proteins of the differentially expressed peptides. (A) The biological process categories. (B) The cellular component categories. (C) The molecular function categories. (D) KEGG signaling pathways. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

viewpoint, which needs more detailed research in order to explain their potential mechanism and function in colon cancer.

The interaction network of peptide precursors

STRING analysis was widely performed to reveal the interaction network of the protein precursors of differentially expressed proteins in various cancer research (19). The interaction between 38 precursor proteins which screened before was examined for the online tool (Figure 4). In summary, there were close associations between most of predicting proteins and 2 primary groups were divided significantly. ALB, which was associated with various cancer types, plays a central role in connection with other several precursors proteins. Besides that, there are also strong connection from HIST2H2AA to other target proteins.

Interestingly, although 2 studies reported this protein in bladder and lung cancer, there are limited relevant studies for its function in colon cancer (20,21). Overall, there were positively associations between proteins we identified and some proteins might have potential roles in colons cancer which remain unscreened at present, such as ALB and HIST2H2AA. However, more studies are warranted to investigate these differential proteins in the future.

Advanced genes associated peptides validation by TCGA and OncoLnc

The TCGA is a publicly funded project to discover comprehensive “atlas” of cancer genomic profiles and has been application in abundant research. Based on the potential function of proteins obtained from above results, the mutated frequency and survival cure for

Table 3 Detailed potential function of top 10 differential expressed protein at present

	Gene name	Key words of potential function	Reference
Up-regulated	IFITM3	Prognosis relevance	Dawei Li <i>et al.</i> (14),
	HIST1H2BC	Prognosis relevance	XiaoJun Xie <i>et al.</i> (12)
	HIST2H3A	Unknown	Unknown
	HBB	Prognosis relevance	David S. Black <i>et al.</i> (13)
	KRT18	Cell differentiation/Notch1 pathway	Lahdeniemi, IA <i>et al.</i> (15)
Down-regulated	IGKV2-30	Unknown	Unknown
	A2M	Biomarkers & prognosis relevance	Ma Yanlei <i>et al.</i> (16) & Chen Jie <i>et al.</i> (17)
	HIST1H4A	Unknown	Unknown
	ANXA2P2	Unknown	Unknown
	FGA	Diagnosis relevance/potential biomarker	Wang Hao <i>et al.</i> (18)




Figure 4 The interaction network analysis of precursor proteins by STRING. This Database predicted the protein-protein interaction associated with determined differential peptides and 2 major groups were separated obviously. ALB, FGA, A3M, LTF, and others were included into 1 major group whereas HIST2H2AA, HIST1H4F, and so on were combined into another group. STRING, Search Tool for the Retrieval of Interacting Genes/Proteins.




Figure 5 The potential function prediction of gene relative to 38 differential peptides. (A) Identification of mutated frequency in up-regulated genes. (B) Determination of mutated frequency in down-regulated genes. (C) Survival curve estimation of HIST2H2AA3 by OncoLnc (high and low percentiles are 50%, respectively).

genes corresponding all proteins (divided into up and down regulated respectively) were estimated in TCGA and OncoLnc respectively (Figure 5). In up-regulated genes, ALB had 6% mutated frequency with negative response HIST2H2AA3 in 199 cases, whereas in down-regulated genes, mutated frequency distributed from 1% (TMSB10) to above 20% (AHNAK) in 256 cases. Besides that, high expression of HIST2H2AA3 might reveal the lower survival rate ($P=0.0442$) estimated by OncoLnc (lower, high percentile were 50% separately). Overall, the genes-associated differential peptides might have higher mutated possibilities, which have potential function in tumorigenesis or prognosis. We hold the opinion that some genes including *ALB* and *HIST2H2AA3* need to be explored about their potential functions in colon cancer in the future.

Discussion

Peptidomics, as an emerging branch of proteomics aimed at producing protein fragments (22), could be used to screen for amounts of disease biomarkers from serum (23), and tissues (24). The current recommended screening includes immunohistochemistry (IHC) and/or microsatellite instability (MSI) test, which gives different results for a given germline mutation sometimes (25). Evidence has displayed that significant biological differences between the CRC tissue and adjacent epithelial tissue (26,27). In recent years, an increasing number of endogenous peptides have been found to exert antitumor activity, such as the peptides derived from therapy-sensitive cancer cells that can overcome therapeutic resistance (28), and the hexapeptide PGPIP_N derived from milk inhibited the metastasis of ovarian cancer cells (29). In colon cancer, the HOXB-

AS3 peptide encoded by long non-coding RNA (lncRNA) HOXB-AS3 inhibited cancer growth (30). As was shown in previously mentioned literatures, peptides have been closely linked to a variety of biological processes and functions (31,32). However, the relationship between peptidomics and malignant CRC is poorly understood. Our study is the first to qualitatively compare differentially expressed peptides of CRC tissue and adjacent epithelial tissue patients. This study may pave the way for researching diagnosis and treatment markers of the CRC.

Following the experimental process, we extracted peptides fragments from CRC tissue and adjacent epithelial tissue samples by molecular weight cut off filters of 10 kDa, which could ensure the purity of the extracted peptides. In a result, 133 peptides were detected in the 6 samples, indicating that this is an effective method for extracting low-molecular-mass peptides. Functional studies of the identified peptides were conducted: 25 peptides were up-regulated and 34 peptides were down-regulated (abundance changed >2-fold) in CRC tissues compared with adjacent epithelial tissues by LC-MS/MS analysis.

Furthermore, online pI/MW tool was used to analyze the differentially expressed peptides. The results showed that the MWs of the 59 peptides were mainly distributed from 1,200 to 2,200, and the MWs of 99% of the peptides were less than 2,200, and the scope of the vast majority was 1,200 to 1,800 (79.7%). Hence, we speculated that the peptides with low MW might play a major role during the development of CRC which again highlights the effectiveness of the MWCO filter. In addition, the largest proportion of peptide pI ranged from 6 to 7, accounting for 33.9% of all peptides. In the study, we found that the most start amino acids of peptides was lysine (K), accounting for 26% in up and down regulated amino acids respectively. Lysine is an essential amino acid, necessary for human health, which seems to help the body to absorb calcium. The stoichiometry of lysine acetylation has not been explored in cancer, representing a promising field in which to increase our knowledge of how this modification is affected in cancer (33). Therefore, we suggested that the identified peptides of this study might be the key regulating factors during the CRC development progression.

Until now, the function of these different peptide precursor proteins has been poorly understood. Thus, we attempted to identify these peptidome and peptide precursors protein differentially expressed to obtain more useful information for us before the further research. Firstly, the GO analysis indicated that the molecular and

cell functions of the peptides precursors mainly involved in antioxidant activity, macromolecule metabolic process, nucleus, catalytic step 2 spliceosome, which were often associated with the development and progression of tumor. Secondly, in addition, pathways (drug metabolism-cytochrome P450, tyrosine metabolism, OC signaling, metabolism of xenobiotics by cytochrome P450), participated in the occurrence of CRC. Thus, the peptides derived from these protein precursors could be putative bioactive peptides for CRC. Subsequently, we analyzed the significantly differentially expressed top 10 peptides, of which there were 5 up-regulated peptides: IFITM3, HIST1H2BC, HIST2H3A, HBB, and KRT18 and 5 down-regulated peptides: IGKV2-30, A2M, HIST1H4A, ANXA2P2, and FGA in the 54 differentially expressed peptides by the online tool SMART. Interestingly, the results showed that some have been reported through literature retrieval. IFITM3, which could be induced by interferon (IFN), is closely associated with pediatric tuberculosis in the Han Chinese Population (34,35). IFITM3 knockdown could induce cell cycle arrest in glioma cells (36). Meanwhile, Li *et al.* reported that IFITM3, mediated with KLF4, was overexpressed in human CRC (14). Furthermore, Fan *et al.* validated IFITM3 as the biomarker of early colon cancer (37). Ghosh *et al.* found that HBB could mediate the development of various cancers including colon cancer (38). Drew *et al.* forecasted that KRT18, named Keratins 18, could be considered as a molecular marker in colon adenomatous polyp and carcinoma identification (39). Interestingly, there have been few functional studies of HIST1H2BC and HIST2H3A in colon cancer. For example, Xie *et al.* considered this target gene a potential influencing element in prognosis of CRC (12). The role of HIST2H3A, which is considered a DNA-binding factor, has remained unclear in colon cancer to date. Based on the obvious differences identified and relevant function, we think that this gene needs more investigation in cancer research in the future. Furthermore, HIST1H4A and ANXA2P2 play an important role in DNA or phospholipid binding, suggesting their potential biological function in colon cancer.

To unravel the network of these proteins, the interaction between all targets was analyzed by online tool STRING. Obviously, ALB and HIST2H2AA (HIST2H3A) were at central location of all networks. ALB could be introduced as a possible biomarker related to colon cancer grade II to III transition (40). Given the speculation of differential gene expressions from our study, mutated frequency distribution

in these genes were determined according to TCGA database to seek their variation. Notably, HIST2H2AA3 has no mutation in 199 cases which detected with higher FC rate in our study. Furthermore, the survival curve of this gene was estimated in OncoLnc for the evaluation of its potential value. Interestingly, higher expression of this gene predicted poor prognosis ($P < 0.05$). Thus, we concluded that this gene might play an indispensable role in colon cancer, such as enhancing downstream genes expressions or according to their DNA-binding function. Based on the knowledge of persistent synthesis of HIST2H2AA3 during S-phase to package the newly replicated DNA, it might be considered as one medium for proliferation or migration in colon cancer in our review (41).

However, our study also had some shortcomings. Firstly, although we used 3 CRC tissue samples to analyze the differentially expressed peptides, the heterogeneity of the cancer population was not ruled out. The sample size was also insufficiently large. Secondly, we did not synthesize differentiated peptides for further functional verification, the function of the differentially expressed peptides in CRC progression still needs to be further investigated.

Shortly, this study screened differentially expressed peptides preliminarily based on TMT labeling combined with MS LC-MS/MS using CRC tissue samples and adjacent epithelial tissue samples from patients and has proven to be a new search for sensitive especially non-invasive tumor markers and therapeutic targets for CRC. We will also aim to validate the potential value of the above differential expression peptides as early diagnostic markers or potent therapeutic targets of CRC by expanding clinical specimens to a considerable number. Investigation is lastly required to assess the specific function and mechanism of these peptides with the CRC.

Conclusions

Shortly, this study investigated the peptides with great difference preliminarily based on TMT labeling combined with LC-MS/MS using colorectal cancer tissue samples and adjacent epithelial tissue samples from patients. Our methods have proved to be a new approach for tumor diagnostic or therapeutic markers in CRC with great sensitivity. We still need more clinical trials to validate these peptides as potential cancer biomarkers in later study with a considerable case number. Meanwhile, investigation is lastly required to assess the specific function and mechanism of them with the CRC.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the STREGA reporting checklist. Available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-188/rc>

Data Sharing Statement: Available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-188/dss>

Peer Review File: Available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-188/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-188/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (No. 2018-SRFA-268). The patients were informed about the research and signed medical informed consent documents.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. *N Engl J Med* 2009;361:2449-60.
2. Brenner H, Kloor M, Pox CP. Colorectal cancer. *Lancet* 2014;383:1490-502.

3. Wan XB, Wang AQ, Cao J, et al. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. *World J Gastroenterol* 2019;25:808-23.
4. Osseis M, Nehmeh WA, Rassy N, et al. Surgery for T4 Colorectal Cancer in Older Patients: Determinants of Outcomes. *J Pers Med* 2022;12:1534.
5. Mousavi S, Moallem R, Hassanian SM, et al. Tumor-derived exosomes: Potential biomarkers and therapeutic target in the treatment of colorectal cancer. *J Cell Physiol* 2019;234:12422-32.
6. Grillet F, Bayet E, Villeronce O, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. *Gut* 2017;66:1802-10.
7. Kirana C, Ruskiewicz A, Stubbs RS, et al. Soluble HLA-G is a differential prognostic marker in sequential colorectal cancer disease stages. *Int J Cancer* 2017;140:2577-86.
8. Boussios S, Ozturk MA, Moschetta M, et al. The Developing Story of Predictive Biomarkers in Colorectal Cancer. *J Pers Med* 2019;9:12.
9. Leichtle AB, Dufour JF, Fiedler GM. Potentials and pitfalls of clinical peptidomics and metabolomics. *Swiss Med Wkly* 2013;143:w13801.
10. Huang X, Zhou J, Tang R, et al. Potential Significance of Peptidome in Human Ovarian Cancer for Patients With Ascites. *Int J Gynecol Cancer* 2018;28:355-62.
11. Xu J, Wang X, Xu P, et al. Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues. *Int J Biochem Cell Biol* 2019;107:53-61.
12. Xie XJ, Liu P, Cai CD, et al. The Generation and Validation of a 20-Genes Model Influencing the Prognosis of Colorectal Cancer. *Journal of Cellular Biochemistry* 2017;118:3675-85.
13. Black DS, Cole SW, Christodoulou G, et al. Genomic mechanisms of fatigue in survivors of colorectal cancer. *Cancer* 2018;124:2637-44.
14. Li D, Peng Z, Tang H, et al. KLF4-mediated negative regulation of IFITM3 expression plays a critical role in colon cancer pathogenesis. *Clin Cancer Res* 2011;17:3558-68.
15. Lähdeniemi IAK, Misiorek JO, Antila CJM, et al. Keratins regulate colonic epithelial cell differentiation through the Notch1 signalling pathway. *Cell Death Differ* 2017;24:984-96.
16. Ma Y, Zhang P, Wang F, et al. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. *Ann Surg* 2012;255:720-30.
17. Chen J, Zhou Y, Xu Y, et al. Low pretreatment serum globulin may predict favorable prognosis for gastric cancer patients. *Tumour Biol* 2016;37:3905-11.
18. Wang H, Luo C, Zhu S, et al. Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts. *Oncotarget* 2017;8:59376-86.
19. Tang D, Zhao X, Zhang L, et al. Identification of hub genes to regulate breast cancer metastasis to brain by bioinformatics analyses. *J Cell Biochem* 2019;120:9522-31.
20. Havaleshko DM, Cho H, Conaway M, et al. Prediction of drug combination chemosensitivity in human bladder cancer. *Mol Cancer Ther* 2007;6:578-86.
21. Shiba-Ishii A, Kano J, Morishita Y, et al. High expression of stratifin is a universal abnormality during the course of malignant progression of early-stage lung adenocarcinoma. *Int J Cancer* 2011;129:2445-53.
22. Latosinska A, Siwy J, Mischak H, et al. Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future. *Electrophoresis* 2019;40:2294-308.
23. Dai Y, Hu C, Wang L, et al. Serum peptidome patterns of human systemic lupus erythematosus based on magnetic bead separation and MALDI-TOF mass spectrometry analysis. *Scand J Rheumatol* 2010;39:240-6.
24. Chen C, Xiao D, Zhou W, et al. Comparative peptidome analyses of the profiles of the peptides ranging from 1-10 KD in CSF samples pooled from probable sporadic CJD and non-CJD patients. *Prion* 2012;6:46-51.
25. Adeleke S, Haslam A, Choy A, et al. Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. *Per Med* 2022;19:277-86.
26. Liu R, Su X, Long Y, et al. A systematic review and quantitative assessment of methylation biomarkers in fecal DNA and colorectal cancer and its precursor, colorectal adenoma. *Mutat Res* 2019;779:45-57.
27. Jothimani G, Sriramulu S, Chabria Y, et al. A Review on Theragnostic Applications of Micrnas and Long Non-Coding RNAs in Colorectal Cancer. *Curr Top Med Chem* 2018;18:2614-29.
28. Wang W, Gu F, Wei C, et al. PGPIP, a therapeutic hexapeptide, suppressed human ovarian cancer growth by targeting BCL2. *PLoS One* 2013;8:e60701.
29. Zhao M, Wei C, Yang X, et al. The milk-derived hexapeptide PGPIP inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes. *Int J*

- Oncol 2016;48:1721-9.
30. Huang JZ, Chen M, Chen, et al. A Peptide Encoded by a Putative lncRNA HOXB-AS3 Suppresses Colon Cancer Growth. *Mol Cell* 2017;68:171-84.e6.
 31. Neves LX, Granato DC, Busso-Lopes AF, et al. Peptidomics-Driven Strategy Reveals Peptides and Predicted Proteases Associated With Oral Cancer Prognosis. *Mol Cell Proteomics* 2021;20:100004.
 32. Foreman RE, George AL, Reimann F, et al. Peptidomics: A Review of Clinical Applications and Methodologies. *Journal of Proteome Research* 2021;20:3782-97.
 33. Gil J, Ramirez-Torres A, Encarnacion-Guevara S. Lysine acetylation and cancer: A proteomics perspective. *J Proteomics* 2017;150:297-309.
 34. Shen C, Li YJ, Yin QQ, et al. Identification of differentially expressed transcripts targeted by the knockdown of endogenous IFITM3. *Mol Med Rep* 2016;14:4367-73.
 35. Shen C, Wu XR, Jiao WW, et al. A functional promoter polymorphism of IFITM3 is associated with susceptibility to pediatric tuberculosis in Han Chinese population. *PLoS One* 2013;8:e67816.
 36. Zhao B, Wang H, Zong G, et al. The role of IFITM3 in the growth and migration of human glioma cells. *BMC Neurol* 2013;13:210.
 37. Fan J, Peng Z, Zhou C, et al. Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses - Identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. *Cancer* 2008;113:266-75.
 38. Ghosh A, De RK. Fuzzy Correlated Association Mining: Selecting altered associations among the genes, and some possible marker genes mediating certain cancers. *Applied Soft Computing* 2016;38:587-605.
 39. Drew JE, Farquharson AJ, Mayer CD, et al. Predictive Gene Signatures: Molecular Markers Distinguishing Colon Adenomatous Polyp and Carcinoma. *Plos One* 2014;9:20.
 40. Rostami-Nejad M, Rezaei Tavirani S, Mansouri V, et al. Gene expression profile analysis of colon cancer grade II into grade III transition by using system biology. *Gastroenterol Hepatol Bed Bench* 2019;12:60-6.
 41. Lyons SM, Cunningham CH, Welch JD, et al. A subset of replication-dependent histone mRNAs are expressed as polyadenylated RNAs in terminally differentiated tissues. *Nucleic Acids Res* 2016;44:9190-205.

Cite this article as: Xu J, Li X, Chen W, Cheng SY, Cheng J, Chen C. Peptidomic changes in human serous colorectal cancer patients. *J Gastrointest Oncol* 2023;14(2):705-718. doi: 10.21037/jgo-23-188

Table S1 Characteristics of all peptides identified by LC-MS

Accession	Protein	Sequence	Parent Ion Weight	Spectral charge-mass ratio (m/z)	Confidence level (>95%)	Fold Change	Standard Deviation	P-Value
P26373	RL13	QLTGPMVPV	1244.71	623.36	99.00	0.76	0.24	0.07
P18085	ARF4	TTIPTIGFNVETV	1694.95	848.48	99.00	2.56	3.06	0.56
P23528	COF1	ASGVAVSDGVIKVF	1693.96	847.99	99.00	0.36	0.47	0.01
Q09666	AHNK	ADLDVSGPK	1508.87	755.44	99.00	0.21	0.25	0.00
P84243	H33	GALQEASEAYLV	1553.82	777.92	98.35	5.01	3.17	0.20
P62899	RL31	KNLQTVNVN DEN	1881.05	941.53	99.00	0.33	0.39	0.01
P08670	VIME	ASSPGGVYATRSSAV	1712.90	857.46	99.00	8.05	6.26	0.20
P62807	H2B1C	TSREIQTAV	1307.72	654.87	99.00	13.24	8.34	0.02
P84243	H33	GLFEDTNLCAI	1555.79	778.90	99.00	3.03	1.85	0.00
P23528	COF1	ASGVAVSDGVIKV	1546.89	774.45	99.00	1.88	1.62	0.73
Q6F113	H2A2A	AQGGVLPNIAQAV	1469.85	735.93	99.00	6.94	2.66	0.00
P01023	A2MG	YGAATFTR	1189.63	595.82	99.00	0.51	0.44	0.02
P62328	TYB4	SDKPDMAEIEK	1912.01	957.01	99.00	0.14	0.09	0.00
P08670	VIME	SYVTTSTRTYS	1568.79	785.40	99.00	0.37	0.63	0.01
P06454	PTMA	SDAAVDTSEITTK	1769.88	885.95	99.00	1.58	1.45	0.71
P51911	CNN1	FEPGLGMEH	1319.65	660.83	98.85	--	--	--
P0DOX7	IGK	DSTYLSSTLTLSK	2110.16	1056.09	99.00	0.60	0.48	0.02
P02652	APOA2	VELGTQPATQ	1346.74	674.38	99.00	1.00	0.79	0.47
P61513	RL37A	AGGAWTYNTT	1344.66	673.34	99.00	2.98	0.19	0.03
P50213	IDH3A	FTGGVQTV	1111.61	556.81	99.00	3.14	3.02	0.16
P10412	H14	SETAPAAPAAPAPAEK	1823.96	912.99	99.00	0.08	--	--
A6NMY6	AXA2L	LLYLCGGDD	1328.66	665.34	99.00	0.49	0.18	0.00
P32322	P5CR1	GFTAAGVL	1038.60	520.31	99.00	--	--	--
P02647	APOA1	THLAPYSDELIR	1300.65	651.33	99.00	0.77	0.49	0.23
P02671	FIBA	GEGDFLAEGGGVR	1566.79	784.40	99.00	0.48	0.29	0.05
Q9H1H9	KI13A	TDYQVTLQIPAA	1622.95	812.48	99.00	--	--	--
Q6ZT98	TTL7	SRGQGLW	1106.56	554.29	99.00	--	--	--
P17213	BPI	VNPGVV	986.60	494.31	98.14	--	--	--
P08670	VIME	SLYASSPGGVYATR	1731.92	866.97	99.00	0.17	0.24	0.10
P28070	PSB4	TQNPMTGTSVLGV	1706.93	854.47	99.00	0.60	0.11	0.15
P10082	PYY	DGPDTLISK	1552.85	777.43	95.67	1.12	1.74	0.28
P04406	G3P	SAPSADAPMFV	1395.70	698.86	98.70	2.53	1.21	0.08
P02671	FIBA	FDTASTGK	1433.80	717.91	99.00	0.44	0.45	0.02
P05787	K2C8	VSESSDVLPK	1668.93	557.32	99.00	--	--	--
Q01628	IFM3	APHNPAPTST	1491.80	746.91	99.00	14.94	16.80	0.01
P69905	HBA	VLSPADKTNV	1650.96	551.33	99.00	6.45	3.01	0.00
Q6F113	H2A2A	IAQGGVLPNIAQAV	1582.94	792.48	99.00	1.22	0.79	0.87
Q14165	MLEC	AAGAGLPESV	1174.65	588.33	99.00	--	--	--
P08670	VIME	YASSPGGVYATR	1531.79	766.90	99.00	0.17	0.10	0.03
P68871	HBB	VHLTPEEKSAV	1817.05	909.53	99.00	9.91	3.39	0.00
P05787	TYB10	GGLTSPGLSYS	1341.71	671.86	99.00	--	--	--
P63313	TYB10	ADKPDMGEIAS	1478.72	740.37	99.00	0.32	0.22	0.00
P26641	EF1G	LFGTNSSSI	1342.70	672.36	99.00	2.52	2.98	0.41
P05787	K2C8	SAYGGLTSPGLSYSLG	1832.97	917.49	99.00	0.33	0.38	0.20
Q71DI3	H32	DLRFQSSAV	1325.71	663.86	97.56	11.88	6.26	0.00
Q6F113	H2A2A	GAGAPVYMAAV	1325.69	663.85	99.00	0.65	0.08	0.00
Q14847	LASP1	SVVADTPELQR	1517.85	759.93	99.00	0.02	0.02	0.10
Q9BQE3	TBA1C	EIDLVLDR	1388.83	695.42	99.00	0.52	0.33	0.13
P62937	PPIA	VNPTVF	979.56	490.79	97.44	2.70	2.47	0.52
P62829	RL23	SLGLPVGAV	1115.68	558.85	99.00	1.06	0.75	0.72
P10412	H14	TKAVAASKERSGV	1954.14	652.39	99.00	5.55	5.44	0.01
P39023	RL3	TIVETPPMVV	1404.78	703.40	99.00	--	--	--
P05787	K2C8	SESSDVLPK	1568.89	785.45	99.00	0.07	0.05	0.00
P02768	ALBU	AASQAALGL	1104.63	553.32	99.00	4.34	4.65	0.20
P06312	KV401	DIVMTQSPDSLAV	1678.88	840.45	97.92	1.86	1.04	0.22
P68104	EF1A1	AVGVIAKAV	1102.70	552.36	99.00	--	--	--
P63261	ACTG	MYVAIQAV	1197.67	599.84	99.00	9.45	--	--
P10082	PYY	TFFPDGEDRPV	1582.79	792.40	99.00	0.07	0.02	0.00
P02768	ALBU	SQAALGL	962.56	482.29	95.44	--	--	--
Q71DI3	H32	MALQEASEAYLV	1643.84	822.93	99.00	--	--	--
P51911	CNN1	GASQAGMTAPGTK	1783.97	892.99	99.00	0.34	0.30	0.00
P02671	FIBA	DTASTGKTFPG	1688.92	845.46	97.96	3.20	2.50	0.05
Q6F113	H2A2A	YVNLPIINGNGKQ	1664.95	833.48	99.00	4.81	2.84	0.00
Q16777	H2A2C	GGVLPNIAQAV	1270.74	636.38	99.00	2.26	--	--
P62304	RUXE	TLLQSVSN	1164.66	583.34	99.00	2.23	0.31	0.00
Q6F113	H2A2A	AGLQFPVGR	1247.73	624.87	99.00	0.02	0.01	0.01
P02751	FINC	IYLYTLNDNAR	1658.89	830.45	99.00	0.99	0.66	0.36
Q99832	TCPH	NALTAASEAA	1221.65	611.83	99.00	--	--	--
Q16777	H2A2C	QGGVLPNIAQAV	1398.81	700.41	99.00	6.81	3.50	0.00
P01282	VIP	VSSNISEDPVPV	1545.82	773.92	99.00	0.39	0.45	0.00
Q14847	LASP1	SAPVYQQPQQQPV	1772.95	887.48	99.00	0.89	1.08	0.21
P02671	FIBA	ADSGEGDFLAEGGGVR	1839.89	920.95	99.00	0.59	0.73	0.09
P26599	PTBP1	MDGIVPDIAVGTK	1660.91	831.46	99.00	0.33	0.23	0.00
P68431	H31	MALQEACEAYLV	1716.83	859.42	99.00	--	--	--
P10412	H14	AAAGYDVEK	1530.85	766.43	99.00	0.20	0.24	0.00
P16112	PGCA	VPDLSGQPSGLPGFSGATS	1815.86	908.94	99.00	--	--	--
Q92522	H1X	SVELEEALPV	1388.78	695.40	99.00	--	--	--
P02679	FIBG	IHLISTQSAIPY	1341.74	671.88	99.00	--	--	--
P02788	TRFL	QAIAENRADAV	1460.79	731.40	99.00	2.99	2.48	0.02
P09211	GSTP1	NLPINGNGKQ	1662.95	832.48	99.00	8.01	1.95	0.00
Q6F113	H2A2A	TIAQGGVLPNIAQAV	1683.98	843.00	99.00	4.62	1.77	0.00
P62330	ARF6	TTIPTVGFNVETV	1680.95	841.48	99.00	0.38	--	--
P16104	H2AX	GAGAPVYLAA	1192.66	597.34	99.00	0.90	--	--
Q16695	H31T	MALQEACESYLV	1732.85	867.43	99.00	--	--	--
Q16777	H2A2C	GAGAPVYMAA	1226.62	614.32	95.64	1.77	1.09	0.32
P01023	A2MG	HYDGSYSTFGER	1721.80	861.91	99.00	9.99	12.54	0.19
P05787	K2C8	SAYGGLTSP	1155.60	578.81	99.00	--	--	--
P01024	CO3	SYTVAIAGYALAQMR	1991.05	996.53	99.00	--	--	--
P02768	ALBU	YICENQDSISSK	2051.04	1026.53	99.00	6.43	6.12	0.02
Q71UM5	RS27L	TTVFSHAQTV	1393.75	697.88	99.00	3.28	3.12	0.01
Q86SJ6	DSG4	AAGGTVEGGV	1120.58	561.30	99.00	--	--	--
P05787	K2C8	TVNQSLLSPL	1374.80	688.41	98.89	--	--	--
P68871	HBB	VNVDEVGGEALGR	1616.87	809.44	99.00	0.28	0.12	0.00
P10082	PYY	FPDGEDRPV	1334.68	668.35	99.00	0.12	--	--
P02671	FIBA	SGEGDFLAEGGGVR	1653.83	827.92	99.00	0.40	0.05	0.01
P08670	VIME	SYVTTSTRTY	1481.76	741.89	99.00	0.05	0.05	0.00
P04083	ANXA1	AMVSEFLK	1269.69	635.85	99.00	1.04	0.82	0.60
P62805	H4	LENVIRDAVT	1432.82	717.42	99.00	0.51	0.37	0.03
P02768	ALBU	QAALGL	875.53	438.77	99.00	2.08	--	--
P69905	HBA	STVLTSKYR	1661.99	832.00	95.67	7.08	4.45	0.00
P68871	HBB	VHLTPEEKSAVT	1918.10	640.37	99.00	0.79	0.08	0.00
P63261	ACTG	GYSFTTTAER	1435.72	718.87	99.00	0.79	0.51	0.08
P01023	A2MG	QQNAQGGFSSTQDVTVALHALSK	2673.38	892.13	99.00	0.55	0.81	0.02
P05787	K2C8	ESSDVLPK	1481.85	741.93	99.00	0.09	0.07	0.00
P62328	TYB4	SDKPDMAEIEKF	2059.09	1030.55	99.00	0.43	0.31	0.01
Q09666	AHNK	ADVDISGPK	1508.87	755.44	99.00	0.09	0.05	0.00
P26599	PTBP1	GIVPDIAVGTK	1676.90	839.46	97.92	--	--	--
P05783	K1C18	SVQAPSYGARPV	1534.84	768.43	99.00	9.15	3.63	0.00
P30044	PRDX5	SLAPNIISQL	1358.81	680.41	99.00	7.37	5.10	0.00
Q43390	HNRPR	QDTYGGQWK	1760.94	881.48	99.00	0.33	0.53	0.01
P59666	DEF3	DCYCRIPA	1357.64	679.83	99.00	8.18	5.19	0.00
P01023	A2MG	AAQVTIQSSGTFSSK	2119.18	1060.60	99.00	1.05	0.71	0.35
P62424	RL7A	AHDVDPIELV	1410.77	706.39	99.00	0.37	--	--
P22626	ROA2	GGPYGGGNYGP	1298.63	650.32	99.00	0.39	0.53	0.01
P10412	H14	SGVSLAALK	1452.91	727.46	99.00	0.24	0.11	0.03
Q9NQC	RTN4	AAPVPTAPAAGAPL	1506.89	754.45	99.00	0.21	0.20	0.00
Q8NFW1	COMA1	GPPGADGIAGAAGPPG	1580.81	791.41	99.00	0.90	0.36	0.25
P0DOX6	IGM	YAATSQVLLPSK	1885.12	943.57	99.00	--	--	--
P02671	FIBA	GDFLAEGGGVR	1380.73	691.37	95.91	0.26	0.15	0.00
P02768	ALBU	LYEIAIR	1230.69	616.35	99.00	10.08	9.53	0.00
P69905	HBA	VGAHAGEYGAEALER	1832.96	917.49	99.00	0.75	0.66	0.20
P10412	H14	SETAPAAPAAPAPAEKTPV	2121.14	1061.58	99.00	0.96	0.53	0.35
P37802	TAGL2	GASQAGMTGYGMP	1530.72	766.37	99.00	0.82	0.12	0.13
P06310	KV230	DVVMTQSPLSLPV	1688.94	845.48	99.00	0.60	0.23	0.02
P02768	ALBU	ASQAALGL	1033.60	517.81	99.00	15.69	18.38	0.03
P01282	VIP	NISEDPVPV	1272.71	637.36	96.66	9.34	11.89	0.82
P05783	K1C18	SLGSVQAPSYG	1368.71	685.36	99.00	0.77	0.88	0.40
P39023	RL3	TIVETPPMVV	1487.86	744.94	99.00	1.46	--	--
P37802	TAGL2	GASQAGMTGY	1245.60	623.81	99.00	3.89	6.83	0.86
P59666	DEF3	YGTCIYQGR	1420.70	711.36	99.00	0.08	0.06	0.00
P62280	JRS11	ADIQTERAYKQKPT	1994.06	998.04	99.00	6.87	4.79	0.00
P01023	A2MG	AIGYLTNGYQR	1558.85	780.43	99.00	2.22	2.05	0.74
P01023	A2MG	LVHVEEPTETVR	1849.11	617.38	99.00	--	--	--